Latest News

The mobile laboratory forms part of efforts to strengthen Uganda’s public health emergency preparedness following lessons from recent Ebola outbreaks.

The Coordinating Minister of Health and Social Welfare, Prof. Muhammad Ali Pate, issued the directive as the government intensifies efforts to protect children from vaccine-preventable diseases and strengthen the country’s capacity to respond to outbreaks.

The decision follows positive results from the Phase III VALOR trial (NCT05437263), which showed that Lisraya improved several measures of dermatomyositis disease activity.

The hospital will coordinate the collection, while Sidra Medicine will process and store the samples at its specialized Good Manufacturing Practice (GMP) facility, which houses Qatar’s only cord blood bank.

The new site will complement RayzeBio’s existing 77,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, located about 20 miles southwest of Whitestown.

The framework calls on countries to maintain high-quality disease surveillance, preserve laboratory and emergency response capacity, strengthen routine immunization and secure sustainable domestic financing.

These therapies can require multiple stages, including DNA starting materials, RNA production, targeted delivery technologies, formulation, analytical testing and scalable drug product manufacturing.

The Center provides round-the-clock support to healthcare facilities across Moscow and analyzes more than 180,000 computed tomography (CT), magnetic resonance imaging (MRI), mammography and X-ray examinations every week.

Under the partnership, M42 will support Botswana’s efforts to transform its healthcare system through digital health, genomics, precision medicine and workforce development.

Uganda completed the monitoring period without detecting further transmission, providing an additional safeguard that no transmission chains linked to the imported case had been missed.